Cohance Lifesciences Limited has informed the Exchange about Resignation of Director/KMP/SMP

Kmp ResignedDirector Flagged GovernanceCeo Appointed ExternalManagement Changes View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.1%Reaction day

₹432.10

prior close

₹444.45

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.0%+13.0% vs market

Pharmaceuticals peers, median of 165sector-0.3%+13.4% vs sector

On the reaction day the stock moved 13.0 pts more than Nifty Smallcap 250 and 13.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+7.5

10m

+9.8

15m

+10.5

30m

+14.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.1+0.0+13.0-0.3+13.4

Next day

+8.8+0.5+8.2-0.4+9.2

+11.2+0.1+11.1-0.8+12.0

+8.1+1.1+7.0+0.5+7.5

+5.1+1.3+3.8+0.5+4.6

+11.6+3.1+8.5+1.8+9.8

+12.7+4.3+8.4+3.3+9.4

15d

-2.9-0.2-2.7+1.5-4.3

-0.2+1.7-1.9+3.0-3.2

+4.1+5.4-1.3+6.0-1.9

-1.6+6.2-7.8+6.4-8.1

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vivek Sharma has resigned as Executive Chairman and Director of Cohance Lifesciences Limited, effective April 30, 2026, citing personal reasons. He served during the company's important growth phase and thanked the board, management, employees, and customers. Simultaneously, Umang Vohra has been appointed as the new Executive Chairman effective May 1, 2026. Vohra brings over 30 years of experience, having previously served as Managing Director and Global CEO of Cipla Limited, and CFO at Dr. Reddys Laboratories.

Likely market impact

The resignation of the Executive Chairman is a significant leadership change, but the immediate appointment of an experienced external leader like Umang Vohra, who previously led Cipla, provides continuity and may reassure investors about the company's strategic direction.